Metronomic Chemotherapy in Elderly Patients: Do Risks Exceed Benefits in Some Patients?

DeMario M.D. , Ratain M.J. : Oral chemotherapy: rationale and future directions. J Clin Oncol, 16: 2557–2567, 1998.

Gately S. , Kerbel R. : Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J, 7: 427–436, 2001.

Colleoni M. , Rocca A. , Sandri M.T. : Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol, 13: 73–80, 2002.

IBCSG 32-05/BIG 1-05: Tailored Chemotherapy trial for women at advanced age with endocrine non-responsive breast cancer: The CASA Trial, available at http://www.ibcsg.org/public/general_pages/trials/open/32-05_big1-05/trial_32-05.shtml (accessed 4 December, 2007).

Extermann M. , Aapro M. , Bernabei R. , Cohen H.J. , Droz J.P. , Lichtman S. , Mor V. , Monfardini S. , Repetto L. , Sørbye L. , Topinkova E. ; Task Force on CGA of the International Society of Geriatric Oncology: Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol, 55: 241–252, 2005.